No Survival Difference With Peregrine's Bavituximab

Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) reported that there was no significant difference in survival rates in a Phase II clinical trial of its bavituximab in patients with Stage IIIb and Stage IV non-small cell lung cancer. Shares of the biopharmaceutical plunged 32 cents to $1.24.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here